|
1
|
Gomaa AI, Khan SA, Toledano MB, Waked I
and Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology,
risk factors and pathogenesis. World J Gastroenterol. 14:4300–4308.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005.
|
|
3
|
Bruix J and Sherman M: American
Association for the Study of the Liver. Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colli A, Fraquelli M, Casazza G, Massironi
S, Colucci A, Conte D and Duca P: Accuracy of ultrasonography,
spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing
hepatocellular carcinoma: a systematic review. Am J Gastroenterol.
101:513–523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nicolau C, Vilana R, Bianchi L and Brú C:
Early-stage hepatocellular carcinoma: the high accuracy of
real-time contrast-enhanced ultrasonography in the assessment of
response to percutaneous treatment. Eur Radiol. 17(Suppl 6):
F80–F88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maruyama H, Yoshikawa M and Yokosuka O:
Current role of ultrasound for the management of hepatocellular
carcinoma. World J Gastroenterol. 14:1710–1719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim SK, Kim SH, Lee WJ, Kim H, Seo JW,
Choi D, Lim HK, Lee SJ and Lim JH: Preoperative detection of
hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir
trisodium-enhanced MR imaging. AJR Am J Roentgenol. 179:741–750.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Snowberger N, Chinnakotla S, Lepe RM,
Peattie J, Goldstein R, Klintmalm GB and Davis GL: Alpha
fetoprotein, ultrasound, computerized tomography and magnetic
resonance imaging for detection of hepatocellular carcinoma in
patients with advanced cirrhosis. Aliment Pharmacol Ther.
26:1187–1194. 2007. View Article : Google Scholar
|
|
9
|
Kudo M: The 2008 Okuda lecture: Management
of hepatocellular carcinoma: from surveillance to molecular
targeted therapy. J Gastroenterol Hepatol. 25:439–452. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trevisani F, D’Intino PE, Morselli-Labate
AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S,
Roda E and Bernardi M: Serum alpha-fetoprotein for diagnosis of
hepatocellular carcinoma in patients with chronic liver disease:
influence of HBsAg and anti-HCV status. J Hepatol. 34:570–575.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gambarin-Gelwan M, Wolf DC, Shapiro R,
Schwartz ME and Min AD: Sensitivity of commonly available screening
tests in detecting hepatocellular carcinoma in cirrhotic patients
undergoing liver transplantation. Am J Gastroenterol. 95:1535–1538.
2000. View Article : Google Scholar
|
|
12
|
Taketa K: Alpha-fetoprotein: reevaluation
in hepatology. Hepatology. 12:1420–1432. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li D, Mallory T and Satomura S: AFP-L3: a
new generation of tumor marker for hepatocellular carcinoma. Clin
Chim Acta. 313:15–19. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malaguarnera G, Giordano M, Paladina I,
Berretta M, Cappellani A and Malaguarnera M: Serum markers of
hepatocellular carcinoma. Dig Dis Sci. 55:2744–2755. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stefaniuk P, Cianciara J and
Wiercinska-Drapalo A: Present and future possibilities for early
diagnosis of hepatocellular carcinoma. World J Gastroenterol.
16:418–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tateishi R, Yoshida H, Matsuyama Y, Mine
N, Kondo Y and Omata M: Diagnostic accuracy of tumor markers for
hepatocellular carcinoma: a systematic review. Hepatol Int.
2:17–30. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huo TI, Hsia CY, Chu CJ, Huang YH, Lui WY,
Wu JC, Lee PC, Chi CW and Lee SD: The predictive ability of serum
alpha-fetoprotein for hepatocellular carcinoma is linked with the
characteristics of the target population at surveillance. J Surg
Oncol. 95:645–651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Volk ML, Hernandez JC, Su GL, Lok AS and
Marrero JA: Risk factors for hepatocellular carcinoma may impair
the performance of biomarkers: a comparison of AFP, DCP, and
AFP-L3. Cancer Biomark. 3:79–87. 2007.PubMed/NCBI
|
|
19
|
Raptis I, Koskinas J, Emmanouil T and
Hadziyannis S: Changing relative roles of hepatitis B and C viruses
in the aetiology of hepatocellular carcinoma in Greece.
Epidemiological and clinical observations. J Viral Hepat.
10:450–454. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamagata Y, Shimizu K, Nakamura K, Henmi
F, Satomura S, Matsuura S and Tanaka M: Simultaneous determination
of percentage of Lens culinaris agglutinin-reactive
alpha-fetoprotein and alpha-fetoprotein concentration using the
LiBASys clinical auto-analyzer. Clin Chim Acta. 327:59–67. 2003.
View Article : Google Scholar
|
|
21
|
Owen WE, Roberts RF and Roberts WL:
Performance characteristics of the LiBASys des-gamma-carboxy
prothrombin assay. Clin Chim Acta. 389:183–185. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kagebayashi C, Yamaguchi I, Akinaga A,
Kitano H, Yokoyama K, Satomura M, Kurosawa T, Watanabe M, Kawabata
T, Chang W, Li C, Bousse L, Wada HG and Satomura S: Automated
immunoassay system for AFP-L3% using on-chip electrokinetic
reaction and separation by affinity electrophoresis. Anal Biochem.
388:306–311. 2009.
|
|
23
|
Eleftheriou N, Heathcote J, Thomas HC and
Sherlock S: Serum alpha-fetoprotein levels in patients with acute
and chronic liver disease. Relation to hepatocellular regeneration
and development of primary liver cell carcinoma. J Clin Pathol.
30:704–708. 1977. View Article : Google Scholar
|
|
24
|
Hsieh SY, He JR, Yu MC, Lee WC, Chen TC,
Lo SJ, Bera R, Sung CM and Chiu CT: Secreted ERBB3 isoforms are
serum markers for early hepatoma in patients with chronic hepatitis
and cirrhosis. J Proteome Res. 10:4715–4724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jirun P, Zhang G, Kim HK, Ha SA, Zhongtian
J, Shishi Q, Zhuqingqing C, Lei G, Yoo J, Kim S, Park YG, Wang J,
Yang Y, Xu Z, Huang Z, Lee YK, Song EY and Kim JW: Clinical utility
of alpha fetoprotein and HCCR-1, alone or in combination, in
patients with chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma. Dis Markers. 30:307–315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, Du X
and Huang ZH: Quantitative methylation analysis of multiple genes
using methylation-sensitive restriction enzyme-based quantitative
PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol.
9:455–460. 2011. View Article : Google Scholar
|
|
27
|
Qu KZ, Zhang K, Li H, Afdhal NH and
Albitar M: Circulating microRNAs as biomarkers for hepatocellular
carcinoma. J Clin Gastroenterol. 45:355–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu T, Xue R, Dong L, Wu H, Zhang D and
Shen X: Rapid determination of serological cytokine biomarkers for
hepatitis B virus-related hepatocellular carcinoma using antibody
microarrays. Acta Biochim Biophys. 43:45–51. 2011.
|
|
29
|
Yasmin Anum MY, Looi ML, Nor Aini AH,
Merican I, Wahidah A, Mohd Radzi AH, Nor Azizah A and Othman NH:
Combined assessment of TGF-beta-1 and alpha-fetoprotein values
improves specificity in the diagnosis of hepatocellular carcinoma
and other chronic liver diseases in Malaysia. Med J Malaysia.
64:223–227. 2009.PubMed/NCBI
|
|
30
|
Kang X, Sun L, Guo K, Shu H, Yao J, Qin X
and Liu Y: Serum protein biomarkers screening in HCC patients with
liver cirrhosis by ICAT-LC-MS/MS. J Cancer Res Clin Oncol.
136:1151–1159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Subwongcharoen S, Leelawat K,
Treepongkaruna SA and Narong S: Serum AFP and AFP-L3 in clinically
distinguished hepatocellular carcinoma from patients with liver
masses. J Med Assoc Thai. 94:S46–S51. 2011.PubMed/NCBI
|
|
32
|
Tanwandee T, Setthasin S,
Charatcharoenwitthaya P, Chainuvati S, Leelakusolvong S, Pausawasdi
N, Srikureja W, Pongprasobchai S, Manatsathit S, Kachintorn U, Ekpo
P and Senawong S: Clinical utility of lens culinaris
agglutinin-reactive alpha-fetoprotein in the diagnosis of
hepatocellular carcinoma: evaluation in a Thai referral population.
J Med Assoc Thai. 92:S49–S56. 2009.
|
|
33
|
Sterling RK, Jeffers L, Gordon F, Venook
AP, Reddy KR, Satomura S and Kanke F: Utility of Lens culinaris
agglutinin-reactive fraction of alpha-fetoprotein and
des-gamma-carboxy prothrombin, alone or in combination, as
biomarkers for hepatocellular carcinoma. Clin Gastroenterol
Hepatol. 7:104–113. 2009. View Article : Google Scholar
|
|
34
|
Donati M, Brancato G and Donati A:
Clinical biomarkers in hepatocellular carcinoma (HCC). Front
Biosci. 2:571–577. 2011.
|
|
35
|
Tamura Y, Igarashi M, Kawai H, Suda T,
Satomura S and Aoyagi Y: Clinical advantage of highly sensitive
on-chip immunoassay for fucosylated fraction of alpha-fetoprotein
in patients with hepatocellular carcinoma. Dig Dis Sci.
55:3576–3583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Toyoda H, Kumada T, Tada T, Kaneoka Y,
Maeda A, Kanke F and Satomura S: Clinical utility of highly
sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in
hepatocellular carcinoma patients with alpha-fetoprotein <20
ng/ml. Cancer Sci. 102:1025–1031. 2011. View Article : Google Scholar
|
|
37
|
Oda K, Ido A, Tamai T, Matsushita M,
Kumagai K, Mawatari S, Saishoji A, Kure T, Ohno K, Toyokura E,
Imanaka D, Moriuchi A, Uto H, Oketani M, Hashiguchi T and Tsubouchi
H: Highly sensitive lens culinaris agglutinin-reactive
α-fetoprotein is useful for early detection of hepatocellular
carcinoma in patients with chronic liver disease. Oncol Rep.
26:1227–1233. 2011.
|
|
38
|
Morimoto M, Numata K, Nozaki A, Kondo M,
Moriya S, Taguri M, Morita S, Konno M, Sugo A, Miyajima E, Maeda S
and Tanaka K: Novel Lens culinaris agglutinin-reactive fraction of
α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence
in patients with low α-fetoprotein concentrations. Int J Clin
Oncol. 17:373–379. 2012.
|
|
39
|
Kobayashi M, Hosaka T, Ikeda K, Seko Y,
Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase
Y and Kumada H: Highly sensitive AFP-L3% assay is useful for
predicting recurrence of hepatocellular carcinoma after curative
treatment pre- and postoperatively. Hepatol Res. 41:1036–1045.
2011.
|
|
40
|
Tong MJ, Sun HE, Hsien C and Lu DS:
Surveillance for hepatocellular carcinoma improves survival in
Asian-American patients with hepatitis B: results from a
community-based clinic. Dig Dis Sci. 55:826–835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Toyoda H, Kumada T, Osaki Y, Oka H and
Kudo M: Role of tumor markers in assessment of tumor progression
and prediction of outcomes in patients with hepatocellular
carcinoma. Hepatol Res. 37(Suppl 2): S166–S171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shiina S, Tateishi R, Arano T, Uchino K,
Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto
T, Yoshida H, Omata M and Koike K: Radiofrequency ablation for
hepatocellular carcinoma: 10-year outcome and prognostic factors.
Am J Gastroenterol. 107:569–577. 2012.PubMed/NCBI
|
